Casi Pharmaceuticals Inc (CASI)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP) in China. "Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options," said Dr. Wei-Wu He, Chairman and CEO of CASI, "The rapid execution underscores our commitment to accelerating clinical development.
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024. Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases.
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.
Casi Pharmaceuticals Inc (CASI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Casi Pharmaceuticals Inc ever had a stock split?
Casi Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | David A. Cory CEO | NASDAQ (CM) Exchange | 14757U208 CUSIP |
| CN Country | 214 Employees | - Last Dividend | 1 Jul 2010 Last Split | 11 Jun 1996 IPO Date |
Overview
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics and pharmaceutical products. With operations spanning across the People's Republic of China, the United States, and internationally, the company is dedicated to addressing critical medical needs within the hematology/oncology space. Established in 1991 and headquartered in Beijing, CASI Pharmaceuticals leverages its global presence and strategic licensing and distribution agreements to advance its product portfolio. These partnerships include collaborations with entities such as Juventas Biotechnology (Tianjin) Co., Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., as well as distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Through these alliances, CASI seeks to both broaden its market reach and enhance its therapeutic offerings.
Products and Services
- EVOMELA
- CNCT 19
- BI-1206
- CB-5339
- CID-103
An intravenous formulation of melphalan primarily used as a conditioning treatment prior to stem cell transplantation, as well as for palliative care in multiple myeloma patients. EVOMELA stands out for its role in enabling successful stem cell transplants by preparing the patient's body to accept the new cells. Its palliative use also provides a means to manage symptoms and improve the quality of life for those suffering from multiple myeloma.
An investigational autologous CD19 CAR-T therapy product focused on the treatment of various hematological malignancies. CAR-T therapy represents a cutting-edge approach in cancer treatment, offering personalized therapy by modifying a patient's T-cells to attack cancer cells. CNCT 19 aims to harness this innovative technology to target and eliminate cancer cells more effectively.
A novel anti-FcγRIIB antibody designed for the treatment of solid tumors and relapsed or refractory non-Hodgkin lymphoma. This therapeutic candidate works by targeting FcγRIIB, a receptor that plays a crucial role in the immune system's ability to fight cancer. By inhibiting this receptor, BI-1206 seeks to enhance the body's natural immune response against cancer cells.
A novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97, targeting it as a novel approach in the treatment of various malignancies. VCP/p97 plays a key role in multiple cellular processes, including protein homeostasis and DNA damage response. Inhibiting VCP/p97 offers a promising strategy in disrupting cancer cell survival mechanisms.
A human IgG1 anti-CD38 monoclonal antibody targeting CD38, a molecule highly expressed in multiple myeloma cells. By targeting CD38, CID-103 aims to induce direct anti-tumor effects as well as immunomodulatory activities, making it a potential therapeutic option for treating multiple myeloma and other CD38-positive malignancies.
